STD Test / Packages

The HIV Western blot test is a diagnostic tool used to confirm the presence of HIV infection. It detects specific proteins (antigens) produced by the human immunodeficiency virus (HIV) in the blood. After separating proteins through gel electrophoresis, they are transferred onto a membrane and probed with antibodies specific to HIV proteins. A positive result indicates the presence of HIV-specific antibodies, confirming an HIV infection. This test is often used as a follow-up to initial screening tests.

The HBsAg ELISA (Enzyme-Linked Immunosorbent Assay) test detects the presence of Hepatitis B surface antigen (HBsAg) in the blood. HBsAg is a protein on the surface of the Hepatitis B virus, indicating active infection. This test is used to diagnose acute or chronic Hepatitis B infection. A positive result suggests that the person is currently infected with the virus, while a negative result indicates the absence of HBsAg, suggesting no current Hepatitis B infection.

The HBsAg (Hepatitis B surface antigen) test using the CLIA (Chemiluminescent Immunoassay) method detects the presence of HBsAg in blood samples. CLIA is a highly sensitive and specific laboratory technique that utilizes chemiluminescence to measure the amount of HBsAg present in the sample. During the test, HBsAg in the sample binds to specific antibodies coated with a chemiluminescent molecule. This binding produces light, which is measured and quantified by a luminometer. The intensity of the light emitted correlates with the concentration of HBsAg in the sample, providing accurate and quantitative results. The CLIA method is widely used in clinical laboratories due to its reliability in detecting low levels of HBsAg and its ability to distinguish between positive and negative results efficiently.

HBsAg rapid test detects the presence of hepatitis B surface antigen (HBsAg) in the blood. HBsAg is a protein on the surface of the hepatitis B virus (HBV) and is one of the earliest markers of HBV infection. The rapid test uses a small amount of blood and provides quick results within minutes, making it useful for screening purposes, especially in resource-limited settings. A positive result indicates current HBV infection, while a negative result suggests the absence of HBV infection at the time of testing. However, further confirmation with additional tests, such as HBV DNA PCR and antibody tests, may be necessary for accurate diagnosis and management of hepatitis B infection.

HCV quantitative testing measures the amount of hepatitis C virus (HCV) RNA present in the blood. This test quantifies the viral load, providing a precise count of viral copies per milliliter. It is essential for assessing the severity of infection, monitoring treatment response, and determining the effectiveness of antiviral therapy. High viral loads may indicate active or more severe disease, while a decrease in viral load during treatment suggests a positive response. Quantitative HCV tests help guide clinical decisions, tailor treatment plans, and evaluate the risk of progression to chronic liver conditions.

The HCV IgM test measures the presence of immunoglobulin M (IgM) antibodies against the hepatitis C virus (HCV) in the blood. IgM antibodies are typically produced early in the course of an infection. Therefore, the HCV IgM test helps detect recent or acute hepatitis C infection. This test is used to diagnose new infections and differentiate between acute and chronic hepatitis C, as IgM levels can indicate recent exposure to the virus.

HCV IgG is a blood test that measures the presence of immunoglobulin G (IgG) antibodies against the hepatitis C virus (HCV). The detection of HCV IgG indicates past or ongoing infection with hepatitis C. Unlike IgM antibodies, which indicate a recent or acute infection, IgG antibodies are typically present in chronic or past infections. This test is used to diagnose hepatitis C, determine if an individual has been exposed to the virus, and help guide further diagnostic and treatment decisions.

HCV genotyping measures the specific strain or type of Hepatitis C virus (HCV) present in a patient’s blood. This test identifies the viral genotype, which is crucial for determining the appropriate treatment regimen and predicting the likelihood of treatment success. HCV has several genotypes, each with multiple subtypes, and knowing the genotype helps tailor antiviral therapy and manage the disease effectively. This test is typically used to guide treatment decisions and monitor the response to therapy.

The HCV total antibodies test using the CLIA (Chemiluminescent Immunoassay) method detects antibodies against Hepatitis C virus (HCV) in blood samples. This test is crucial for diagnosing HCV infection, as it identifies antibodies produced by the immune system in response to the virus. The CLIA technique involves capturing HCV antibodies from the sample using specific antibodies immobilized on a solid surface. A chemiluminescent reaction then generates light in proportion to the amount of HCV antibodies present, which is measured quantitatively. This method is highly sensitive, allowing for early detection of HCV infection and is used for screening individuals at risk, monitoring disease progression, and assessing treatment efficacy in clinical settings.

An HIV rapid test measures the presence of antibodies to the human immunodeficiency virus (HIV) or HIV antigens in the blood, saliva, or urine. This test is designed to quickly screen for HIV infection and provide results within minutes. There are two main types of rapid tests: 1. **Antibody Tests:** Detect antibodies produced by the immune system in response to HIV infection. 2. **Antigen/Antibody Tests:** Detect both HIV antibodies and the HIV p24 antigen, which is a protein associated with the virus. Rapid HIV tests are used for early detection of HIV infection, often in clinical settings, community health programs, or at home. Positive results from a rapid test typically require confirmation with more comprehensive tests, such as a nucleic acid test (NAT) or an enzyme immunoassay (EIA), to ensure accurate diagnosis.

The VDRL (Venereal Disease Research Laboratory) and RPR (Rapid Plasma Reagin) tests are non-treponemal blood tests used to screen for syphilis. They measure antibodies produced in response to substances released during tissue damage caused by the syphilis bacteria. Both tests detect these non-specific antibodies, which may be elevated in syphilis infections. Positive results indicate a potential syphilis infection, but confirmatory treponemal tests are required for accurate diagnosis, as non-treponemal tests can also yield false positives.

HCV total antibodies test detects antibodies produced in response to hepatitis C virus (HCV) infection. A positive result indicates either a current or past infection with HCV. It does not distinguish between acute, chronic, or resolved infections, nor does it measure the virus's presence or activity. A follow-up HCV RNA test is necessary to confirm active infection by detecting viral RNA. False positives can occur, especially in low-risk populations, so confirmatory testing is essential. HCV, a blood-borne virus, primarily spreads through sharing needles, blood transfusions, and, less commonly, sexual contact. Early detection is crucial for managing and potentially curing the infection with antiviral treatments. Regular monitoring and lifestyle adjustments can help prevent liver damage, including cirrhosis and liver cancer, associated with chronic HCV infection.

HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, especially CD4 cells, and can lead to AIDS if untreated. HBsAg (Hepatitis B Surface Antigen) detects active Hepatitis B infection and indicates that the person can transmit the virus. HCV (Hepatitis C Virus) testing identifies infection that mainly affects the liver and may become chronic. VDRL (Venereal Disease Research Laboratory) is a screening test for syphilis that detects antibodies related to the infection. HSV (Herpes Simplex Virus) testing identifies herpes infections, commonly causing oral or genital sores. TPHA (Treponema Pallidum Hemagglutination Assay) is a confirmatory test for syphilis, used to verify VDRL results.

Neisseria gonorrhoeae – Qualitative PCR is a highly sensitive molecular diagnostic test used to detect the presence of Neisseria gonorrhoeae, the bacteria responsible for gonorrhea, a common sexually transmitted infection (STI). This test works by identifying the genetic material (DNA) of the bacteria in clinical samples such as urine or genital swabs. Being a qualitative test, it provides a positive or negative result, indicating whether the infection is present or not, rather than measuring the amount of bacteria. PCR technology allows early and accurate detection, even when symptoms are mild or absent. It is especially useful for screening sexually active individuals and guiding timely treatment, helping prevent complications and further transmission.

The HIV, HBsAg, and HCV rapid tests are diagnostic tools used to screen for different infectious diseases: 1. **HIV Rapid Test:** Detects the presence of antibodies to HIV or the HIV antigen in blood, saliva, or urine. This test helps identify HIV infection, allowing for early diagnosis and prompt treatment. 2. **HBsAg Rapid Test:** Measures the presence of hepatitis B surface antigen (HBsAg) in the blood. A positive result indicates an active hepatitis B virus infection, which can be acute or chronic. 3. **HCV Rapid Test:** Detects antibodies to the hepatitis C virus (HCV) in the blood. A positive result suggests exposure to HCV, and further testing is needed to confirm a current infection and determine the appropriate treatment. All three tests are designed for quick results, usually within minutes, and are often used in health screening programs and point-of-care settings. Positive results typically require confirmation with more detailed laboratory tests.

The HCV (Hepatitis C Virus), HIV (Human Immunodeficiency Virus), HBsAg (Hepatitis B Surface Antigen), and VDRL (Venereal Disease Research Laboratory) tests are used to diagnose and monitor viral infections and sexually transmitted diseases: 1. **HCV (Hepatitis C Virus) Test**: Detects antibodies or viral RNA to determine current or past infection with Hepatitis C. It helps diagnose Hepatitis C, assess infection status, and guide treatment decisions. 2. **HIV (Human Immunodeficiency Virus) Test**: Detects antibodies against HIV or HIV RNA/DNA. It is used to diagnose HIV infection, monitor viral load, and manage treatment in individuals living with HIV. 3. **HBsAg (Hepatitis B Surface Antigen) Test**: Measures the presence of the Hepatitis B surface antigen, indicating an active Hepatitis B infection. It is used to diagnose Hepatitis B and monitor infection status. 4. **VDRL (Venereal Disease Research Laboratory) Test**: A non-treponemal test used to screen for syphilis by detecting reagin antibodies produced in response to cellular damage caused by the infection. Positive results require confirmation with more specific tests. These tests are essential for diagnosing, monitoring, and managing infectious diseases and ensuring appropriate treatment.

TPHA Rapid Test (Treponema Pallidum Hemagglutination Assay) is a diagnostic blood test used to detect antibodies against Treponema pallidum, the bacterium that causes syphilis. The test helps identify current or past exposure to the infection by detecting the body's immune response rather than the bacteria itself. A small blood sample is collected and analyzed, with results typically available within a short time. TPHA is commonly used as a confirmatory test following an initial syphilis screening test. A positive result indicates the presence of antibodies and should be interpreted along with clinical findings and other laboratory investigations.